The new EU Regulation on Health Technology Assessment (HTA) introduces mandatory joint clinical assessments (JCAs) at the EU level for certain medicines and medical devices. As this regulation starts applying from January 2025, it is critical for health technology developers to understand the JCA process and its implications.

Key takeaways

  • JCAs will evaluate the relative clinical effectiveness of a product compared to appropriate comparators, focusing solely on clinical data and not economic aspects.
  • The scope of each JCA (the PICO - population, intervention, comparator, outcomes) will be defined by EU HTA assessors through a survey of member state needs.
  • There could be multiple PICOs requested in a JCA, e.g. to cover different comparators used across member states.
  • JCA timelines are tightly coupled to the EMA marketing authorization process, with key milestones defined in the regulation.

Don't miss out on these important details! Read the full white paper to prepare your company for successfully navigating these new mandatory EU-level clinical evaluations.


Dr Sigrid Klaar

Medical Advisor and Advisory Board Member


You don't have to go it alone!

Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs

This field is for validation purposes and should be left unchanged.